Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a 24-week, prospective, multi-center, open-label, randomized, investigator-initiated
pilot study to explore the effects of RBZ (0.5 mg) plus DEX implant (0.7 mg) PRN combination
therapy (n = 30) vs. DEX implant PRN monotherapy (n = 30) in pseudophakic eyes with
center-involved DME that have demonstrated prior incomplete response to 3-6 anti-VEGF
treatments.